1. Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression
End point
Relative risk (95% CI) p
Doubling of creatinine
0.71 ( )
0.07
End-stage renal disease
0.87 ( )
0.04
Casas JP et al. Lancet 2005; 366:

2. Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs in diabetic nephropathy
End point
Relative risk (95% CI)
Doubling of creatinine
1.09 ( )
End-stage renal disease
0.89 ( )
Casas JP et al. Lancet 2005; 366: